E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer-Reference-Cited by-同舟云学术

E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer

Published:2005-06 Issue:16_suppl Volume:23 Page:512-512
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Goldstein L. J.¹,O’Neill A.¹,Sparano J.¹,Perez E.¹,Shulman L.¹,Martino S.¹,Davidson N.¹

Affiliation:

1. Fox Chase Cancer Ctr, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Montefiore Medcl Ctr, Bronx, NY; Mayo Clinic, Jacksonville, FL; John Wayne Cancer Institute, Santa Monica, CA; Sidney Kimmel Cancer Ctr at Johns Hopkins, Baltimore, MD

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.512

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer;npj Breast Cancer;2023-05-17

2. Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation;npj Breast Cancer;2021-08-06

3. Taxanes for adjuvant treatment of early breast cancer;Cochrane Database of Systematic Reviews;2019-09-02

4. Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?;Resistance to Targeted Anti-Cancer Therapeutics;2017

5. Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 Patients;PLoS ONE;2011-11-01